Stock Screener App

Gratuito -

Installare

2.27

2.58% -0.06

Lakewood Amedex Biotherapeutics Inc (LABT)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Lakewood Amedex Biotherapeutics Inc Borsa (LABT) Ultime notizie

Lakewood-Amedex Biotherapeutics (LABT) investor WFI Equity discloses 8.8% ownership stake - Stock Titan

Lakewood-Amedex Raises $7.5M and Lists on NASDAQ, Shedding $1.5M Debt - Minichart

LABT: Q2 net loss rose sharply on higher R&D and G&A costs; liquidity improved after Series C financing - TradingView

Lakewood-Amedex Biotherapeutics Inc. Q2 2026: Revenue $0 Net loss $(3.90M), EPS $(2.75) — 10-Q Summary - TradingView

Lakewood-Amedex (NASDAQ: LABT) raises $7.5M, expands cash yet flags going concern - Stock Titan

Upcoming and recent IPOs – IPOs calendar - Yahoo Finance Australia

Lakewood-Amedex Biotherapeutics (LABT) Stock Trends and Sentiment 2026 $LABT - marketbeat.com

Lakewood-Amedex Biotherapeutics announces annual shareholder meeting - Bitget

Lakewood-Amedex (NASDAQ: LABT) seeks 100M share authorization and reverse split power - Stock Titan

Lindesfarne LLC reports 8.582% LABT stake in Lakewood-Amedex Biotherapeutics (LABT) filing - Stock Titan

Lakewood-Amedex Biotherapeutics (LABT) Earnings Date and Reports 2026 $LABT - marketbeat.com

Lakewood-Amedex Biotherapeutics Inc. Revenue Breakdown – NASDAQ:LABT - TradingView

Lakewood-Amedex Biotherapeutics, Inc. (LABT) stock price, news, quote and history - Yahoo Finance Singapore

3 Penny Stocks to Watch Today, 7/23/2026 - TipRanks

Lakewood-Amedex Biotherapeutics, Inc. (LABT) Stock Price, News, Quote & History - Yahoo! Finance Canada

Leonard James Deroma Net Worth (2026) - GuruFocus

Lakewood-Amedex Biotherapeutics Inc.Common Stock (Nasdaq:LABT) Stock Quote - FinancialContent

User - The Chronicle-Journal

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Lakewood-Amedex (NASDAQ:LABT) shares jump after Nu-3 news; trading volume more than 200x daily average - TechStock²

Lakewood-Amedex Biotherapeutics Surges as Fresh Nu-3 Data Draws Attention to Its Antibiotic-Resistance Program - Quiver Quantitative

Lakewood-Amedex (LABT) Stock Soars 141% on Breakthrough Nu-3 Resistance Data - parameter.io

Peter Ceccacci Net Worth (2026) - GuruFocus

Kelvin Cooper Net Worth (2026) - GuruFocus

Trending Stocks Today | Lakewood-Amedex Biotherapeutics Shoots up 126.34% - Moomoo

Lakewood-Amedex (LABT) Stock Jumps 141% After Nu-3 Antimicrobial Data Release - CoinCentral

LABT Stock Whipsaws As Traders React To Conference Spotlight - StocksToTrade

LABT Stock Whipsaws As Traders Eye Virtual Forum Exposure - timothysykes.com

Lakewood-Amedex reports resistance data for Nu-3 antimicrobial By Investing.com - Investing.com South Africa

Lakewood-Amedex reports resistance data for Nu-3 antimicrobial - Investing.com

Lakewood-Amedex announces resistance data for Nu-3 - TipRanks

Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria - PR Newswire

Thomas Balzer Net Worth (2026) - GuruFocus

Lakewood-Amedex Biotherapeutics (LABT) Registration filing Summary - Quartr

Lakewood-Amedex Advances Nu-3 Gel Toward Phase 2a Trial - t.co

Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel - Sahm

Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) maps Nu-3 iDFU trial path and IP - Stock Titan

Lakewood-Amedex reports preclinical safety data for Nu-3 gel By Investing.com - Investing.com South Africa

Lakewood-Amedex reports preclinical safety data for Nu-3 gel - Investing.com

Lakewood-Amedex announces preclinical data from Phase 2a clinical trial - TipRanks

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

CEO Chat with Dr. Kelvin Cooper, CEO of Lakewood-Amedex Biotherapeutics - scr.zacks.com

Lakewood-Amedex Biotherapeutics Inc. Actuals & Estimates (NASDAQ:LABT) - TradingView

Enterprise value to EBITDA forward of Lakewood-Amedex Biotherapeutics Inc. – NASDAQ:LABT - TradingView

Lakewood-Amedex Biotherapeutics Company Profile & Introduction - Moomoo

Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers - aol.com

Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers - AOL.com

Lakewood-Amedex Biotherapeutics (LABT) Revenue BreakdownMain Composition - Moomoo

Lakewood-Amedex backs reintroduced PASTEUR Act legislation By Investing.com - Investing.com Nigeria

Lakewood-Amedex supports reintroduction of PASTEUR act - TipRanks

Lakewood-Amedex backs reintroduced PASTEUR Act legislation - Investing.com

Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance - Nasdaq

Lakewood-Amedex supports PASTEUR Act as Nu-3 heads toward Phase 2 - Stock Titan

Price to book forward of Lakewood-Amedex Biotherapeutics Inc. – NASDAQ:LABT - TradingView

Lakewood-Amedex (LABT) Stock Analysis Report | Financials & Insights - Benzinga

MRNA

$63.32

0.52%

RPRX

$58.60

0.07%

ROIV

$36.20

0.22%

INSM

$123.74

2.05%

ALNY

$228.65

0.67%

ONC

$347.48

2.40%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters